Catalyst Wire Dossier Catalyst Wire Dossier

Pandemic Monovalent (H5N1) Influenza Vaccine (Whole Virus Formulation)

Influenza vaccine, H5N1, whole-virus formulation · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pandemic Monovalent (H5N1) Influenza Vaccine (Whole Virus Formulation), covering 2017-05-08 to 2017-05-08. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age [Phase 1]

See pricing